Dynavax Technologies (DVAX -1.40%) is gearing up for a round of capital raising. The company announced today that it aims to float a pair of share offerings in two underwritten public offerings. The first will be an issue of its common stock, while the second will consist of shares of its Series B convertible preferred stock.
Dynavax said it intends to use the proceeds of the offerings to fund the development of, and efforts at regulatory approval for, its HEPLISAV hepatitis B vaccine. It will also use the monies for "general corporate purposes," which include working capital.
Cowen Group's Cowen and Company is the sole book-running manager for both issues.
At the moment, Dynavax has just under 183 million common shares outstanding, and that stock most recently closed at $1.17 per share.
